Chinese Academy of Sciences

Green Valley (shanghai) Pharmaceuticals Co., Ltd.

Shanghai Haihe Pharmaceutical Co., Ltd.

Shanghai Fochon Pharmaceutical Co., Ltd.

Jinan University

Shanghai Green Valley Pharmaceutical Co., Ltd.

Chongqing Fochon Pharmaceutical Co., Ltd.

Haihe Biopharma Co., Ltd.

Shanghai Institute of Materia Medica, Chinese Acad

Meiyu Geng

Jian Ding

Zhenqing Zhang

Jing Ai

Xianliang Xin

Xia Peng

Yi Chen

Zhongping Xiao

Ao Zhang

Xiaoguang Du

Min Huang

Weibo Wang

Lei Jiang

Xingdong Zhao

Ling Chen

Zilan Song

Jianhua Cao

Hua Xie

Jia Tao Li

Lei Li

Qiong Zhang

Jingkang Shen

Ke Ding

Haohan Tan

Weipeng Zhang

Zhengchao Tu

Hongbin Liu

Qiang Tian

Bing Xiong

Xiaomei Ren

Yinchun Ji

Li Xing

Shuai Tang

Danqi Chen

Xuxing Chen

Qianqian Shen

Yucai Yao

Yu Xue

Linjiang Tong

Yang Liu

Wei Zhang

Dongmei Zhang

Xin Wang

Lei Liu

Qi Rong Wang

Fajun Nan

Yubo Zhou

Xianlong Wang

Yanxin Liu

Tongshuang Li

Jing Sun

Rui Tan

Zuwen Zhou

Lihua Jiang

Yangming Zhang

Tao Meng

Anhui Gao

Mingbo Su

Qihong Liu

Yue Rong

Lanping Ma

Linghua Meng

Qiangang Zheng

Lijun Yang

Youhong Hu

Huixin Wan

Li Tan

Xiaoyun Lu

Li Linghu

Yan Zhang

Qingyun Jiang

Zhang Zhang

Yi Zang

Xianlei Fu

Zhao Zhao

Limin Zeng

Feifei Liu

Qian Tan

Yang Dai

Chuiliang Yu

Chaojun Gong

Yaqiu Long

Zhongliang Xu

Xiaojing Lan

Donglin Gao

Chuantao Zha

Shingpan Chan

Jing Al

Wenming Ren

Yuchi Ma

Xiaocong Guan

Yuelei Chen

Yingshen Jin

Lang Wang

Ning Shen

Ying Dong

Yanyan Shen

A compound having Axl and c-Met kinase inhibitory activity, a preparation method therefor and an application thereof are provided. Specifically, provided herein are a compound having the structure represented by formula (I), a preparation method therefor and an application thereof in the preparation of a medication for the treatment and/or prevention of tumor-associated diseases and/or kinase-related diseases.

Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof

The present invention relates to a pyrimido[5,4-b]pyrrolizin compound represented by general formula I, an optical isomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and a use thereof. The compound according to the present invention has good inhibitory activity on the kinase BTK at both the molecular level and the cellular level. Meanwhile, the compound also has good anti-tumor activity and pharmacokinetic properties in vivo.

Pyrimido[5,4-b]pyrrolizin compound, optical isomer thereof, preparation method therefor and use thereof

A fluorine-containing substituted benzothiophene compound and a pharmaceutical composition and an application thereof are described. The compound has the structure as shown in formula (I), in which the definitions of each group and substituent are as described in the description. A preparation method of the compound and an anti-tumor application thereof are also described.

Fluorine-containing substituted benzothiophene compound, and pharmaceutical composition and application thereof

The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m′ is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5.

Composition of mannuronic diacid

Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.

Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof

The invention provides an indolizine compound represented by formula I or a pharmaceutically acceptable salt thereof, a preparation method and a use thereof. The indolizine compound has an inhibitory effect on wild-type and/or mutant EZH2 or EZH1, and is expected to be developed into a novel drug for anti-tumor or for the treatment of autoimmune diseases. 

Indolizine compounds, preparation method and use thereof

The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof. 

Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof

The present invention relates to an alginic oligosaccharic diacid composition comprising a mannuronic diacid of Formula (IV) or a pharmaceutically acceptable salt thereof, wherein n is an integer selected from 1 to 9, m is selected from 0, 1 or 2, m' is selected from 0 or 1, and wherein the total weight of alginic oligosaccharic diacid wherein n=1-5 accounts for more than 60% of the total weight of the composition; the total weight of guluronic acids accounts for less than 50% of the total weight of the composition. 

Composition of alginic oligosaccharic diacids

The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.

Compound having ERK kinase inhibitory activity and use thereof

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease.

Use of mannuronic diacid composition in treatment of Parkinson's disease

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of diabetes.

Use of mannuronic diacid composition in treatment of diabetes

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.

Use of mannuronic diacid composition in treatment of inflammation

The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of pain.

Use of mannuronic diacid composition in treatment of pain

The present invention relates to the application of mannuronic diacid oligosaccharide composition in the treatment of vascular dementia.

Use of mannuronic diacid composition in treatment of vascular dementia

The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m' is 0 or 1, and wherein the total weight of mannuronic diacids wherein n=1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n=1-3 to the total weight of mannuronic diacids wherein n=4-7 is between 1.0 and 3.5. 

Growing community of inventors

Shanghai, China

Meiyu Geng